Literature DB >> 35312959

In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.

Serena L'Abbate1, Michela Chianca1, Iacopo Fabiani2, Annamaria Del Franco1,3, Alberto Giannoni1,3, Giuseppe Vergaro1,3, Chrysanthos Grigoratos3, Claudia Kusmic4, Claudio Passino1,3, Yuri D'Alessandra5, Silvia Burchielli6, Michele Emdin1,3, Daniela Maria Cardinale7.   

Abstract

Modern therapeutic approaches have led to an improvement in the chances of surviving a diagnosis of cancer. However, this may come with side effects, with patients experiencing adverse cardiovascular events or exacerbation of underlying cardiovascular disease related to their cancer treatment. Rodent models of chemotherapy-induced cardiotoxicity are useful to define pathophysiological mechanisms of cardiac damage and to identify potential therapeutic targets. The key mechanisms involved in cardiotoxicity induced by specific different antineoplastic agents are summarized in this state-of-the-art review, as well as the rodent models of cardiotoxicity by different classes of anticancer drugs, along with the strategies tested for primary and secondary cardioprotection. Current approaches for early detection of cardiotoxicity in preclinical studies with a focus on the application of advanced imaging modalities and biomarker strategies are also discussed. Potential applications of cardiotoxicity modelling in rodents are illustrated in relation to the advancements of promising research topics of cardiotoxicity. Created with BioRender.com.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac biomarker; Cardioprotection; Cardiotoxic; Chemotherapy; Rodent model; Ventricular function

Year:  2022        PMID: 35312959     DOI: 10.1007/s12265-022-10231-2

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  87 in total

1.  Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats.

Authors:  Bertha Furlan Polegato; Marcos Ferreira Minicucci; Paula Schmidt Azevedo; Robson Francisco Carvalho; Fernanda Chiuso-Minicucci; Elenize Jamas Pereira; Sergio Alberto Rupp Paiva; Leonardo Antônio Mamede Zornoff; Marina Politi Okoshi; Beatriz Bojikian Matsubara; Luiz Shiguero Matsubara
Journal:  Cell Physiol Biochem       Date:  2015-03-26

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

3.  Hydrogen sulfide attenuates paraquat-induced epithelial-mesenchymal transition of human alveolar epithelial cells through regulating transforming growth factor-β1/Smad2/3 signaling pathway.

Authors:  You-Wei Bai; Meng-Juan Ye; Da-Long Yang; Meng-Ping Yu; Cheng-Fan Zhou; Tong Shen
Journal:  J Appl Toxicol       Date:  2018-09-28       Impact factor: 3.446

4.  Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.

Authors:  Dan L Li; Zhao V Wang; Guanqiao Ding; Wei Tan; Xiang Luo; Alfredo Criollo; Min Xie; Nan Jiang; Herman May; Viktoriia Kyrychenko; Jay W Schneider; Thomas G Gillette; Joseph A Hill
Journal:  Circulation       Date:  2016-03-16       Impact factor: 29.690

5.  Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Authors:  Michael S Ewer; Mary T Vooletich; Jean-Bernard Durand; Myrshia L Woods; Joseph R Davis; Vicente Valero; Daniel J Lenihan
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

6.  Activating Autophagy to Prevent Doxorubicin Cardiomyopathy: The Timing Matters.

Authors:  Aarti Asnani
Journal:  Circ Res       Date:  2021-09-30       Impact factor: 17.367

7.  Nerolidol ameliorates cyclophosphamide-induced oxidative stress, neuroinflammation and cognitive dysfunction: Plausible role of Nrf2 and NF- κB.

Authors:  Ashif Iqubal; Sumit Sharma; Abul Kalam Najmi; Mansoor Ali Syed; Javed Ali; M Mumtaz Alam; Syed Ehtaishamul Haque
Journal:  Life Sci       Date:  2019-09-11       Impact factor: 5.037

Review 8.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.

Authors:  Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu
Journal:  Circ Res       Date:  2019-09-19       Impact factor: 17.367

9.  A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.

Authors:  Spencer C Wei; Wouter C Meijers; Javid J Moslehi; James P Allison; Margaret L Axelrod; Nana-Ama A S Anang; Elles M Screever; Elizabeth C Wescott; Douglas B Johnson; Elizabeth Whitley; Lorenz Lehmann; Pierre-Yves Courand; James J Mancuso; Lauren E Himmel; Benedicte Lebrun-Vignes; Matthew J Wleklinski; Bjorn C Knollmann; Jayashree Srinivasan; Yu Li; Oluwatomisin T Atolagbe; Xiayu Rao; Yang Zhao; Jing Wang; Lauren I R Ehrlich; Padmanee Sharma; Joe-Elie Salem; Justin M Balko
Journal:  Cancer Discov       Date:  2020-11-30       Impact factor: 38.272

Review 10.  Cardiotoxicity of Anthracyclines.

Authors:  Daniela Cardinale; Fabiani Iacopo; Carlo Maria Cipolla
Journal:  Front Cardiovasc Med       Date:  2020-03-18
View more
  1 in total

Review 1.  Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities.

Authors:  Laura Pohl; Jana Friedhoff; Christina Jurcic; Miriam Teroerde; Isabella Schindler; Konstantina Strepi; Felix Schneider; Adam Kaczorowski; Markus Hohenfellner; Anette Duensing; Stefan Duensing
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.